Beneficial effects of glucagon-like peptide 1 receptor agonists on glucose control, cardiovascular risk profile, and non-alcoholic fatty liver disease. An expert opinion of the Italian diabetes society.

MLA

Napoli, Raffaele, et al. “Beneficial Effects of Glucagon-like Peptide 1 Receptor Agonists on Glucose Control, Cardiovascular Risk Profile, and Non-Alcoholic Fatty Liver Disease. An Expert Opinion of the Italian Diabetes Society.” Nutrition, Metabolism, and Cardiovascular Diseases : NMCD, vol. 31, no. 12, Nov. 2021, pp. 3257–70. EBSCOhost, https://doi.org/10.1016/j.numecd.2021.08.039.

APA

Napoli, R., Avogaro, A., Formoso, G., Piro, S., Purrello, F., Targher, G., & Consoli, A. (2021). Beneficial effects of glucagon-like peptide 1 receptor agonists on glucose control, cardiovascular risk profile, and non-alcoholic fatty liver disease. An expert opinion of the Italian diabetes society. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD, 31(12), 3257–3270. https://doi.org/10.1016/j.numecd.2021.08.039

Chicago

Napoli, Raffaele, Angelo Avogaro, Gloria Formoso, Salvatore Piro, Francesco Purrello, Giovanni Targher, and Agostino Consoli. 2021. “Beneficial Effects of Glucagon-like Peptide 1 Receptor Agonists on Glucose Control, Cardiovascular Risk Profile, and Non-Alcoholic Fatty Liver Disease. An Expert Opinion of the Italian Diabetes Society.” Nutrition, Metabolism, and Cardiovascular Diseases : NMCD 31 (12): 3257–70. doi:10.1016/j.numecd.2021.08.039.